theoria-creative-logo-icon-dark

Deal-Making Communications

Strategic positioning and communications for high-stakes financing, partnership, and transaction objectives.

Private Investor Readiness

Preparing to raise private capital?

Define or rebuild the investment case, connect science to business value, develop investor materials, and prepare for investor meetings.

Public Investor Readiness

Preparing to engage public-market investors?

Refine the presentation, data flow, talk track, and supporting materials around a consistent investment case.

Business development Conversations

Exploring licensing, co-development, or a strategic partnership?

Position the program, platform, or company around partner value, strategic fit, evidence, and development potential.

Commercial Launch Fundraising

Completed a pivotal study and preparing to finance launch?

Build the financing narrative around market readiness, capital requirements, use of proceeds, launch priorities, and upcoming milestones.

Exit Readiness

Considering out-licensing, a company sale, or another strategic transaction?

Maximize the strategic value of the company and its assets by clearly framing the pipeline, market position, and future potential for prospective buyers.

Examples of Work:

7 Metagenomi-biotech-company-prevalence
Title slide from Sonoma Bio's investor deck introducing their focus on applying the natural abilities of regulatory T cells (Tregs) to modulate immune response and repair tissue damage. The illustration depicts immune cell interactions within the human body.
LEXEO-Company-Presentation-Our-platform-scaled
Addition Therapeutics investor presentation
An illustrative slide, for Enlivex Therapeutics' investor deck, explaining the disease manifestation of osteoarthritis. It outlines the market potential of this disease and the current standard of care.
Fundraising presentation slides created for San Francisco Opera
avenzoar-oncology-company-presentation-biotech
This slide from an AmMax Bio investor deck explains minimal residual disease (MRD) in colorectal cancer (CRC) and its potential to lead to liver metastasis. Illustrations of the colon, a magnifying glass highlighting MRD, and the liver are shown. The slide also mentions circulating tumor DNA (ctDNA) as a biomarker.
Dunad slide 3
This slide from Leap Therapeutics illustrates how DKK1 expression is determined using RNAscope, showing examples of low and high DKK1 patient samples and explaining the methodology. This supports the rationale for targeting DKK1 in specific patient populations.
This slide introduces the OTT Lab for Organ Engineering, within Iviva Medical's presentation, featuring Harald C. Ott, M.D., from Harvard Medical School and Massachusetts General Hospital. It highlights their research in orthotopic transplantation of bioengineered lung grafts, engineered pancreases, intestinal grafts, myocardium, vasculature, kidneys, and hearts, along with a timeline of related publications in prominent scientific journals.
This infographic illustrates the cell processing steps involved in manufacturing cell and gene therapies, which is central to Mustang Bio's work. It shows the processes of leukapheresis or bone marrow harvest, quality control, cell isolation (T cells or stem cells), transduction or engineering, cell reproduction, and final infusion.
This slide from Inhibrx outlines their strategy of leveraging protein engineering, including single-domain antibodies, recombinant proteins, and engineered cytokines, to move from therapies for validated targets towards the development of next-generation therapeutics.
This slide illustrates how genetic alterations in the HIPPO pathway drive oncogenesis across multiple cancer indications, including Esophageal and Head and Neck Cancers, Lung Squamous Cancer, and Ovarian, Uterine, Endometrial, and Cervical Cancer. It depicts the regulated and deregulated HIPPO pathway, leading to YAP/TAZ dependent transcription and tumor growth.
This slide outlines key investment highlights for Werewolf Therapeutics, including their potent targeted cytokine therapies, proprietary PREDATOR platform, a robust pipeline delivering for patients, and their experienced team. Visuals represent immune cell activation, the drug platform, clinical development timelines, and the leadership team.
This slide from Axonis outlines their key therapeutic areas to address common pathologies across neurological disorders. These include 'Protecting neurons' to preserve neurological functions, 'Restoring balance' of excitation/inhibition in dysfunctional neuronal circuits, and 'Regenerating neurons' to restore lost nervous system connections. A central graphic with interconnected nodes visually represents their approach to CNS therapeutics.
This slide positions Frazier Life Sciences as a fully-integrated investment firm, showing a flow from 'creation' (early stage) through 'private' to 'public' investments. It also provides key metrics such as the number of companies funded, Frazier-founded companies, new companies founded per year, IPOs, acquisitions, and their current public portfolio value.
This slide highlights the key features of ALX148 as a superior CD47 blocker. It emphasizes its high affinity CD47 binding domain of SIRPα, its mutated Fc domain that eliminates binding activity to avoid dose-dependent cytopenia, and the presence of the Fc domain ensuring slow clearance and long half-life for less frequent dosing. A diagram illustrates the ALX148 antibody structure with an inactive Fc domain.
This diagram illustrates the central role of C3 in the complement cascade, a key part of the immune system. It shows how the Alternative Pathway, Lectin Pathway, and Classical Pathway all converge on C3, leading to downstream effects like membrane attack, phagocytosis, and inflammation. This highlights the target of Apellis's therapeutic development.

Work

Services

Presentations

We develop conceptual, graphics-driven corporate presentation materials for high-stakes meetings

Scientific Illustrations
We develop messaging, corporate story, content and graphics to ensure top quality of the final product – presentation deck.
Branding
We provide marketing design services to our existing customers.
Web design
We provide marketing design services to our existing customers.

About

Theoria creative
Our history, philosophy concept, team information
Oksana Bovt
Meet the founder Theoria Creative
Testimonials
Lorem ipsum dolor sit amet, consectetur dipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
FAQ
Lorem ipsum dolor sit amet, consectetur adipiscing elit